The Editors’ views: Drug Target Review’s 2020 round-up
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
List view / Grid view
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
A new subspace mass spectrometry imaging method has enabled researchers to provide data sets exponentially faster.
Dr Diogo Camacho from the Wyss Institute at Harvard discusses new research into using machine learning algorithms to analyse RNA sequences and reveal potential drug targets.
The novel probes, known as positive controls, could make it easier to validate rapid, point-of-care diagnostic tests for COVID-19 across the globe.
Bioanalytical systems have rapidly developed over the past 10 years for lead selection during cell-line development. The advanced technologies for the timely and cost-effective screening of antibodies or vaccines involve consideration of quantitation, kinetics and other critical quality attributes (CQA).
In this in-depth focus find out how genetic screening can be used to customise healthcare and why scientists have turned to machine learning in the fight against antimicrobial resistance.
The Automated Recommendation Tool (ART) uses machine learning to accelerate the development of cells for specified goals, eg, bioprocessing and bioproduction.
A new tool called COVID-3D that monitors SARS-CoV-2 genome mutations could aid drug and vaccine development, its creators say.
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
Researchers have developed a way for a microrobot to bioprint new cells directly onto gastric wounds inside the body, which they tested in cells.
A team has developed a predictive tool called TransComp-R which could be used to reveal whether new drugs that have been effective in animals will have positive outcomes in humans.
A flow mode Raman-activated cell sorter called FlowRACS has been created by researchers for high-throughput discovery of enzymes and their cell factories.
Researchers say computational analyses suggest the bradykinin system may explain some of the symptoms of COVID-19, providing a drug target.
Researchers have developed MorphEUS, a technology to identify new drugs that combat M. tuberculosis by revealing how compounds destroy the bacteria.